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Abstract: In this work we studied the functional differences between the microcirculation of murine tumours 
that only express single isoforms of vascular endothelial growth factor-A (VEGF), VEGF120 and VEGF188, 
and the effect of VEGF receptor tyrosine kinase (VEGF-R TK) inhibition on their functional response to the 
vascular disrupting agent, combretastatin A-4 phosphate (CA-4-P). We used measurement of fluorescently-
labelled red blood cell  (RBC) velocities in tumour microvessels  to study this  functional  response.  RBC 
velocity  for  control  VEGF120-expressing  tumours  was  over  50%  slower  than  for  control  VEGF188-
expressing tumours, which may be due to the immature and haemorrhagic vasculature of  the VEGF120 
tumour.  After  chronic  treatment  with  a  VEGF-R  tyrosine  kinase  inhibitor,  SU5416,  RBC velocities  in 
VEGF120 tumours  were significantly  increased  compared  to  control  VEGF120 tumours,  and similar  to 
velocities in both VEGF188 treatment groups. Control and SU5416 treated VEGF188 tumours were not 
different from each other. Treatment of VEGF120 tumours with SU5416 reduced their vascular response to 
CA-4-P to a similar level to the VEGF188 tumours. Differential expression of VEGF isoforms not only 
affected vascular function in untreated tumours but also impacted on response to a vascular disrupting drug, 
CA-4-P,  alone  and  in  combination  with  an  anti-angiogenic  approach  involving  VEGF-R TK inhibition. 
Analysis of RBC velocities is a useful tool in measuring functional responses to vascular targeted treatments.
Keywords: Red Blood Cell Velocity, Microcirculation, Tumour Vasculature, Keyhole Tracking Model
1. Introduction
Vascular  endothelial  growth  factor-A 
(commonly known as VEGF)(Ellis & Hicklin, 
2008) is the predominant protein involved in 
normal  and  tumour  angiogenesis,  a  process 
crucial for the supply of oxygen, nutrients and 
growth factors to  tumours (Folkman,  1990). 
The  VEGF  gene  undergoes  alternative 
splicing  to  produce  multiple  functional 
isoforms, such as 121, 165 and 189 in human 
(Tischer et al., 1991) and 120, 164, and 188 in 
the mouse (Shima et al., 1996). Fibrosarcoma 
cell  lines  have  been  developed  to  express 
single isoforms of VEGF and used to  study 
their roles in tumour vascularisation. Tumours 
expressing  only  VEGF120  are  well 
vascularised, but present with immature blood 
vessels  that  are  fragile  and  leaky  and  the 
tumours  are  prone  to  haemorrhage, 
particularly  when grown in  the  dorsal  skin-
flap  window chamber  model,  where  vessels 
struggle to penetrate beyond the tumour edge 
(Tozer et  al.,  2008).  VEGF188  expressing 
tumours have a lower vascular volume than 
VEGF120 tumours, but the blood vessels are 
much more  mature,  showing good levels  of 
pericyte  coverage  and  less  haemorrhage 
(Tozer et al., 2008). 
Vascular  disrupting  agents  (VDAs)  are  a 
group  of  compounds  that  selectively  target 
tumour  vasculature  and  cause  a  devastating 
collapse  of  blood  flow  in  solid  tumours, 
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culminating in tumour cell death. It is thought 
that  VDAs  preferentially  target  immature 
tumour  blood  vessels,  with  most  evidence 
derived from VDAs that are tubulin-binding 
and  endothelial  cytoskeleton  disrupting 
(Tozer et  al.,  2005b). Disodium 
combretastatin A4 3-O-phosphate (CA-4-P) is 
the  lead  tubulin-binding  VDA  and  studies 
have  shown  that  VEGF120  tumours  that 
present  with  immature  vessels  showed 
reduced vascular and growth response to CA-
4-P,  compared  with  VEGF188  tumours  that 
possess  a  more  mature  vascular  network 
(Tozer et al., 2008).
The VEGF receptor family of proteins belong 
to  the  protein  tyrosine  kinases  that  regulate 
multiple cellular processes that contribute to 
tumour  development  and  progression, 
including  cell  proliferation,  differentiation 
and  cell  survival  (Baselga,  2006,  Blume-
Jensen  &  Hunter,  2001),  and  many  human 
tumours  exhibit  aberrant  tyrosine  kinase 
activity  that  drives  their  growth.   Tyrosine 
kinase inhibitors therefore represent attractive 
anti-tumour  or  anti-vascular  targets  in  the 
clinic (Arteaga, 2003, Baselga, 2006). Several 
multi-target  tyrosine  kinase  inhibitors  that 
include  targeting  VEGF  receptors  have 
reached clinical practice or are in clinical trial 
(Faivre et  al.,  2007,  Drevs et  al.,  2007). 
Under some dosing strategies, treatment with 
VEGFR-2  receptor  antibodies  or  small 
molecule  inhibitors  can  result  in  tumour 
vascular  ‘normalisation’,  whereby  vascular 
morphology  is  altered  and  blood  flow  is 
improved over a limited time-frame (Winkler 
et al., 2004, Jain, 2003, Jain, 2005). However, 
very  little  is  known  about  how  chronic 
tyrosine kinase inhibitors affect the function 
and  morphology  of  the  surviving  blood 
vessels  in  tumours,  and  how  this  affects 
subsequent  treatment  stratagems.  We sought 
to  investigate  the  effects  of  tyrosine  kinase 
receptor  inhibition  on  the  development  of 
tumours expressing single isoforms of VEGF, 
and  their  subsequent  response  to  CA-4-P 
treatment. 
2. Methods
All  experiments  were  conducted  in 
accordance with the United Kingdom Home 
Office  Animals  (Scientific  Procedures)  Act 
1986 and with local ethical approval. CA-4-P 
was kindly provided by Professor GR Pettit, 
Arizona State University.
2.1 VEGF isoform cell lines and tumours
Development  of  cell  lines  is  described 
previously  (Tozer  et  al.,  2008),  but  briefly, 
primary mouse embryo fibroblasts expressing 
only single isoforms of VEGF (120, 164 or 
188) or all isoforms were isolated from 13.5 
days post-coitum (dpc) embryos produced by 
heterozygous breeding pairs of single VEGF 
isoform-expressing  mice  on  a  Swiss 
background.  Fibroblast  cultures  were 
genotyped, as described (Vieira et al., 2007), 
to  identify  wild-type  samples  and  those 
homozygous  for  the  Vegfa120,  Vegfa164  or 
Vegfa188  allele. Fibroblasts were immortalised 
and  oncogenically  transformed  by  retroviral 
transduction  with  SV40  and  HRAS  (h-ras) 
(Parada et al., 1984, Greco et al., 2005).
2.2 Window Chambers 
All  surgery  was carried  out  on  male  severe 
combined  immunodeficiency  (SCID)  mice 
(12-16  week-old,  28-32g)  under  general 
anaesthesia  using  intraperitoneal  (i.p) 
injection of fentanyl citrate (0.8mg•kg-1) and 
fluanisone  (10mg•kg-1;  Hypnorm,  Janssen 
Animal  Health)  and  midazolam  (5mg•kg-1; 
Hypnovel, Roche, Welwyn Garden City, UK). 
Animals  were  kept  warm  during  surgical 
procedure,  and  aseptic  technique  was  used 
throughout. Surgical procedures are similar to 
those  described  previously  (Tozer et  al., 
2005a).  Briefly,  animals  were  shaved, 
depilated and a 15 mm diameter circular area 
of  dorsal  skin  was removed,  as  well  as  the 
subcutaneous (s.c.)  fat  and connective tissue 
of  the  opposing  skin  layer,  leaving  the 
exposed  panniculus  muscle.  An  aluminium 
window  chamber  (total  weight  ∼ 2g), 
designed to hold two parallel  windows, was 
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implanted  onto  the  dorsal  skin.  A  tumour 
fragment  (∼ 0.5  mm  in  diameter,  either 
VEGF120 or 188) from a donor animal was 
implanted  onto  the  exposed  panniculus 
muscle  and the  chamber  was  closed  with  a 
glass window to provide a depth of 200  µm 
for  tumour  growth.  Sub-cutaneous  dextrose 
saline  and  intraperitoneal  buprenorphine 
(Vetergesic)  were  used  to  aid  recovery  and 
animals were kept in a warm room, 28-30 °C, 
until  the  day  of  experiment.  Animals  were 
grouped for treatment and received either the 
VEGF-R  tyrosine  kinase  inhibitor,  SU5416 
(50 mg•kg-1, at a concentration of 25 mg•ml-1 
subcutaneously) or vehicle control (50  µl  of 
DMSO per mouse) as used previously  (Fong 
et al.,  1999) starting at  day 3 after  implant, 
and  then  given  every  4th day  until  further 
experimentation. 
2.3 Red Blood Cell labelling 
Donor  red blood cells  (RBC) were obtained 
via cardiac puncture from donor male SCID 
mice  and  labelled  with  the  fluorescent  dye 
1,1',  di-octadecyl-
3,3,3'3'tetramethylindocarbocyanine 
perchlorate (DiI)  (Molecular  Probes, 
Cambridge  Biosciences,  UK)  for  the 
measurement of RBC velocity in the tumour 
vasculature.  The  labelling  method  has  been 
published previously  (Unthank et  al.,  1993), 
but  briefly  the  RBCs  were  separated  from 
blood  plasma  and  white  blood  cells  by 
centrifugation  and  the  isolated  and  washed 
RBCs incubated with DiI for 30 mins. 25 µg 
of DiI was used per 50 µl of packed RBCs. 
After incubation the RBCs were washed and 
resuspended in phosphate buffered saline (50 
µl•ml-1 RBC-DiI complex). The labelled cells 
were kept for 3 days at 4°C. 
2.4 Intravital Microscopy 
Intravital microscopy permits the observation 
of RBC movement in microvessels  of small 
animals under both normal  and pathological 
conditions  (Sandison, 1924). The analysis of 
RBC  velocities  is  used  in  many  areas  of 
research,  to  measure  the  responsiveness  to 
vasoactive  drugs  (Prazma et  al.,  1989)  or 
response to vascular disrupting agents (Tozer 
et al.,  2001). Approximately 7-11 days after 
surgery, when the tumours reached ∼ 3.0 mm 
in diameter, mice were given 0.2 ml (i.v.) of 
the  RBC-DiI  complex  and  treated  with  a 
single dose of the vascular disrupting agent, 
CA-4-P (30mg•kg-1, iv at a concentration of 3 
mg•ml-1  in 0.9 % NaCl) and monitored for 24 
hours to observe changes in RBC velocity. An 
inverted Nikon Eclipse E600FN fluorescence 
microscope with modified stage to take mice 
was  used.  Tumours  were  viewed  under 
transmitted  light  for  morphological  vessel 
analysis  and  under  epi-fluorescence 
illumination using a 100 W mercury arc lamp 
for  measurement  of  RBC  velocity. 
Fluorescence was set  up to excite  at  550nm 
and detect the emissions at  565nm from the 
labelled  RBCs  using  a  custom-made 
fluorescence cube (Nikon, UK).
2.5 Velocity Analysis
RBC  velocities  were  calculated  from  data 
recorded at x20 magnification with the same 
region  of  interest  used  at  each  time  point. 
Velocities  were  calculated  using  a  keyhole 
tracking  algorithm  performed  in  Matlab,  as 
described previously (Reyes-Aldasoro et  al., 
2008).
The  tracking  algorithm  consisted  of  three 
main steps: pre-processing which transformed 
the videos into a sequence of binary images 
that contained segmented foreground objects 
(RBCs).  Computational  complexity  was 
reduced, noise and artefacts removed and the 
centroids  of  the  RBCs  were  determined 
together  with  the  distances  that  separated 
them  from  neighbours,  if  any.  Tracking, 
which linked the objects in contiguous frames 
to  form  the  tracks  by  means  of  a  keyhole 
model,  which  predicted  the  most  probable 
landing position of a RBC at time  t+1 from 
the position in times  t-1 and  t.  The keyhole 
model  was  formed  by  the  union  of  two 
regions where the RBC is  most  probable to 
land:  a  wedge  and  a  circle  that  combined 
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create the keyhole model. Once all segmented 
RBCs  have  been  examined  for  possible 
parent-child relationships,  a reduced number 
of them formed a series of tracks of different 
lengths.  Post-processing removed  links  in 
tracks  that  could  have  resulted  from  noise, 
and joined sections that were considered to be 
split  sections from a single track.  The same 
keyhole  model  was  used  analysing  the 
movement  backwards.  That  is,  the  same 
keyhole  model  used  child  (t+1)  and 
grandchild (t+2) to generate a keyhole at time 
(t). If the RBC of a previous time point was 
found to land inside the keyhole, it remained 
as part of the track, otherwise it was removed. 
Finally  outliers  were  removed:  those  tracks 
whose  average  velocity  exceed  3  times  the 
standard  deviation  from  the  mean  average 
velocity  of  the  whole  distribution  were 
discarded. 
This process relies on the probability of RBC 
movement  and  allows  analysis  of  all  cells 
over  a  time period rather  than a  select  few. 
Velocity  was  calculated  at  µm•s-1 from  the 
number  of  video frames  taken  for  each  red 
cell to travel between two points of measured 
distance. Fig 1a shows a sample fluorescence 
image where the bright spots describe RBCs 
and  colour  lines  describe  the  tracks  for  a 
single frame and Fig. 1b shows all the tracks 
detected for a video sequence.
2.6 Statistics
Statistical analysis was performed using SPSS 
version  11.0.2  for  the  Apple  Macintosh. 
Student’s unpaired  t-test was used to test for 
significant  differences  between  two  groups. 
Time-course  experiments  were  measured 
using  a  mixed  design  ANOVA for  repeated 
measures with between subjects factors used 
for  tumour  type  and  VEGFG-R  tyrosine 
kinase receptor inhibitor treatment,  followed 
by Tukey (HSD) post-hoc tests correction.
3. Results
At the 0 min time-point, immediately prior to 
CA-4-P  injection,  the  RBC  velocity  of 
VEGF120 tumours treated with  vehicle  was 
188 ± 4 µm•s-1 which was significantly lower 
than  the  VEGF-R  tyrosine  kinase  inhibitor-
treated  VEGF120  tumours,  389  ±  7  µm•s-1 
and both VEGF188 tumour groups (untreated, 
354 ± 7  µm•s-1 and treated 344 ± 6  µm•s-1). 
There was no significant  difference between 
either treatment groups for VEGF188 or the 
VEGF-R  tyrosine  kinase  inhibitor  treated 
VEGF120 tumours (Fig. 2).
Fig 1 Tracks obtained from a video sequence. 
(a) A single frame with several RBCs and 6 
tracks. (b) All the tracks detected in the video 
as a 3D plot with time as the z-axis. Colour of 
the tracks denotes the velocity
The time-course of RBC velocity response to 
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CA-4-P,  for  the  different  tumour  types  ± 
SU5416  treatment,  is  shown  in  Figure  3. 
Control  VEGF120  tumours  without  SU5416 
pre-treatment, were much more responsive to 
CA-4-P  than  VEGF188  tumours,  as  shown 
previously (Tozer et al., 2008). 
Fig. 2  Quantitative analysis of average RBC 
velocity of tumours grown within the dorsal 
skin-flap window chamber, just prior to CA-
4-P  treatment.  Results  indicate  that  the 
receptor  tyrosine  kinase  inhibitor,  SU5416, 
significantly  increased  RBC  velocity  in 
VEGF120  tumours  to  similar  levels  as 
VEGF188 tumours. SU5416 treatment had no 
effect on RBC velocity in VEGF188 tumours. 
* represents P < 0.05 significance compared 
to VEGF120 untreated tumours. 
In  VEGF120  tumours,  RBC  velocity  was 
reduced  to  approximately  20%  of  its  pre-
treatment value by 3 hours after CA-4-P and 
did not recover within 24 hours, whereas, in 
VEGF188  tumours,  RBC velocity  reduction 
was never more than approximately 60% of 
pre-treatment level and fully recovered to pre-
treatment  level  by  24  hours.  However, 
SU5416  pre-treatment  significantly  reduced 
the effect of CA-4-P in the VEGF120 tumours 
(P < 0.05) (Fig. 3a), such that RBC velocity 
had returned to control values by 3 hours after 
CA-4-P  treatment.  In  VEGF188  tumours, 
SU5416  pre-treatment  also  significantly 
decreased the RBC velocity response to CA-
4-P (P < 0.05), even though this tumour type 
was  intrinsically  more  resistant  to  CA-4-P 
than the VEGF120 tumours (Fig. 3b). 
Fig. 3 Quantitative analysis RBC velocities of 
tumours grown in the dorsal skin-flap window 
chamber. Repeated measures analysis indicate 
significant  differences  between  treatment 
groups  for  both  VEGF120  and  VEGF188 
tumours for RBC velocities. * represents P < 
0.05  for  the  difference  between  groups 
receiving VEGF-R TK inhibition and vehicle 
controls.
Between  subjects  comparison  of  VEGF120 
and  VEGF188  tumour  responses  indicates 
that  untreated  tumours  were  significantly 
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differently from each other across the 24 hr 
time course for RBC velocities (F1,16 = 8.62, 
P <  0.05)  whereas  the  responses of  tumour 
lines  treated  with  SU5416  were  not 
significantly different from each other. It was 
also  found  that  the  responses  of  SU5416 
treated  VEGF120  tumours  were  not 
significant  from  the  untreated  VEGF188 
tumour (Fig. 3).
4. Conclusions
Treatment  with  CA-4-P  caused  significant 
reduction in RBC velocity, with no recovery 
over 24 hours, in VEGF120 tumours, whereas 
VEGF188 tumours were much more resistant. 
However,  pre-treatment  with  the  tyrosine 
kinase  VEGF  receptor  inhibitor,  SU5416, 
modified  the  vasculature  of  VEGF120 
tumours,  such  that  RBC  velocity  was 
increased  and  response  to  CA-4-P  was 
reduced.  SU5416  had  no  effect  on  RBC 
velocity  of  VEGF188  tumours  but  also 
reduced their response to CA-4-P. 
These data support the notion that VEGF188 
tumours,  with  mature  stable  vasculature 
(Tozer  et  al.,  2008),  are  protected  from the 
effects  of  CA-4-P,  whereas  the  immature 
blood  vessels  in  VEGF120  tumours  are 
rapidly  broken  down.  Tyrosine  kinase 
inhibition  with  SU5416  significantly 
increased RBC velocity in individual vessels 
of  VEGF120  tumours,  which  was 
accompanied  by  decreased  vascularization 
(data not shown). SU5416 and similar agents 
were designed to block tumour angiogenesis 
by  interfering  with  VEGF-mediated  effects 
such  as  endothelial  proliferation  and 
migration.  However,  the  current  results 
support existing evidence that a sub-optimal 
anti-angiogenic effect can result in a rarefied 
tumour  vascular  bed,  which  nevertheless  is 
efficiently perfused and capable of sustaining 
tumour growth (vascular normalization) (Jain, 
2005).  In  addition,  we  show  that  vascular 
normalization can reduce the efficacy of the 
so-called vascular disrupting agents (VDAs), 
which are  designed to target the established 
tumour  vasculature.  Further  studies  are 
required  to  investigate  the  vascular 
morphological  changes  that  take  place  as  a 
result  of  tyrosine  kinase  inhibition.  It  is 
possible that there is an increase in pericyte 
coverage of these vessels, which would imply 
improved support and resistance against CA-
4-P treatment. VEGF188 tumour response to 
CA-4-P was also reduced following SU5416 
alone treatment, despite no effect of SU5416 
on  RBC  velocity,  and  this  result  requires 
further  mechanistic  investigation,  including 
analysis of vascular morphology. 
 
This study shows that vascular normalization 
following  anti-angiogenic  treatment  with  a 
VEGF-R  tyrosine  kinase  inhibitor  can  have 
unexpected  consequences  for  subsequent 
treatment  outcome.  Analysis  of  RBC 
velocities  in  tumours,  using  the  novel 
algorithm  described,  is  a  useful  tool  in 
measuring  functional  responses  to  vascular-
targeted treatments.
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